Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China

Table 7 Summary of the results of undiscounted and discounted point estimations of measured outcomes in base case analysis comparing infliximab maintenance therapy vs conventional maintenance therapy in the constructed decision analytic model

Model outputs	Results of base-case analysis without discounting			Results of base-case analysis with discounting
	IMT	CMT	Difference	IMT	CMT	Difference
Overall survival in yr	43.815	40.944	2.871	23.858	22.947	0.911
Disease remission before surgery	30.433	13.157	17.276	18.102	9.392	8.710
Active disease before surgery	1.398	2.540	-1.142	0.803	1.788	-0.985
Disease remission after surgery	11.407	20.893	-9.486	4.709	9.701	-4.993
Active disease after surgery	0.576	4.354	-3.777	0.244	2.066	-1.821
Total QALY	33.365	30.889	2.476	18.392	17.491	0.901
Disease remission before surgery	23.450	10.220	13.230	14.066	7.288	6.778
Active disease before surgery	0.973	1.803	-0.831	0.566	1.278	-0.711
Disease remission after surgery	8.553	15.889	-7.335	3.592	7.492	-3.900
Active disease after surgery	0.389	2.977	-2.588	0.168	1.433	-1.266
Total reimbursed medical costs	¥469958	¥373757	¥96201	¥242107	¥192336	¥49771
Drug costs	¥156606	¥48359	¥108246	¥84553	¥25062	¥59491
Surgery costs	¥8261	¥28346	-¥20085	¥4019	¥14511	-¥10492
Disease remission management	¥284675	¥226987	¥57687	¥143601	¥116897	¥26704
Active disease management	¥20417	¥70065	-¥49648	¥9934	¥35866	-¥25932
Total patient out-of-pocket costs	¥726433	¥163918	¥562515	¥431392	¥109111	¥322281
Drug costs	¥629970	¥27629	¥602340	¥374967	¥18346	¥356622
Surgery costs	¥2526	¥11736	-¥9210	¥1452	¥7840	-¥6387
Disease remission management	¥87695	¥95541	-¥7846	¥51383	¥63547	-¥12165
Active disease management	¥6243	¥29012	-¥22769	¥3590	¥19378	-¥15789
Total medical costs	¥1196392	¥537676	¥658716	¥673499	¥301447	¥372052

IMT: Infliximab maintenance therapy; CMT: Conventional maintenance therapy; QALY: Quality-adjusted life years.